Preserving lean body mass through adequate protein and resistance training helps maintain metabolic rate
The expanding therapeutic benefits of GLP-1 drugs: GLP-1 receptor agonists, initially intended for diabetes care, are now shifting the paradigm of chronic disease treatment
These include: G-protein coupled receptor (GPCR) family C group 6 subtype A (GPRC6A), Taste Rs (amino acids), G-protein coupled receptor 93 (GPR93) (peptones), free-fatty acid receptor 2 (FFAR2), free-fatty acid receptor 3 (FFAR3), short-chain fatty acid (SCFA), free-fatty acid receptor 1 (FFAR1), free-fatty acid receptor 4 (FFAR4), long-chain fatty acid (LCFA) and G-protein coupled receptor 119 (GPR119) [oleoylethanolamide (oea)] are some of the macronutrient-sensing receptors present on enteroendocrine cells (Spreckley and Murphy, 2015)
Studies have found that those taking retatrutide lost significantly more weight than those taking a placebo
It is distinguished in the research literature by its selectivity: published pre-clinical work reports it stimulates GH release without significantly elevating cortisol, prolactin, or ACTH, unlike earlier secretagogues in its class
Covariates included were age, booking BMI, systolic and diastolic blood pressure, smoking history, parity and GDM treatment
